Monoclonal Antibodies Market

Monoclonal Antibodies Market – Overview

Monoclonal antibody (mAb) therapy is a type of immunotherapy that uses monoclonal antibodies to attach mono specifically to specific cells or proteins. Monoclonal antibodies are defined as replicas of a parental cell that is derived from identical immune cells, each unique from one another. Such antibodies have the ability to bind to specific antigens during the time of administration, owing to their monovalent affinity. The monoclonal antibodies also serve as a crucial tool for the detection or purification of substances, owing to their site-specificity. Thus, they are highly used in end-use industries such as molecular biology, medicine, and biochemistry. The increasing demand from the industries listed above are liklely to aid in expansion of the overall monoclonal antibodies market during the forecast period set between 2021 and 2031.

The rising prevalence of various types of cancer and the increasing demand for biosimilars antibodies at cost-efficient prices are likely to emerge as the key factors augmenting the growth of the global monoclonal antibodies market. Besides this, the increasing awareness about the availability of robust drugs pipelines among physicians and patients both will also add boost to the overall growth of the market.

The report on the global monoclonal antibodies market offers qualitative and quantitative analysis of the market and its growth parameters. It also emphasizes on the key drivers, restraints, challenges, and upcoming growth opportunities that will impact the market as well as create challenging scenarios. It also focuses on the table of segmentation and mentions the name of the main fragment and its credited elements. The effect of the novel COVID19 pandemic and its credited factors are also highlighted in this report. The number of key players and their critical systems to draw in huge incomes is listed completely in the report.

Monoclonal Antibodies Market – Nature of Competition

Almost all manufacturers of the global monoclonal antibodies market are involving in license agreement renewal, collaborative efforts, and merger and acquisition strategies to gain significant revenues and establish a strong position in the overall market competition. Besides this, some players are also investing heavily on research and development of better antibodies, thus striving for the top position in the overall market competition.

Some of the key players of the global monoclonal antibodies market include:

• Pfizer
• GlaxoSmithKline Plc
• Novartis
• Eli Lily
• Merck & Co. Inc.
• AstraZeneca plc.
• Bayer AG
• Abbott Laboratories
• Johnson & Johnson
• Amgen Inc.
• Others

Monoclonal Antibodies Market – Innovations

• A partnership was signed between MacroGenics Inc. and Incyte in October 2017 alonh with a license agreement for an investigational monoclonal antibody belonging to MacroGenics Inc., called MGA012.
• The launch of adalimumab biosimilars called Amgevita was announced by Amgen in October 2018 in Europe.

Monoclonal Antibodies Market – Drivers

Technological advancement for the development of molecular level of disease study, coupled with the rising applications of monoclonal antibodies is considered significant growth drivers for the global monoclonal antibodies market. Besides this, rising geriatric population and their vulnerability towards various chronic diseases especially cancer are likely to augment the demand for various antibodies, thereby boosting the growth of the overall market during the forecast period set between 2021 and 2031.

Monoclonal Antibodies Market – Geographical Segmentation

Regionwise, the global monoclonal antibodies market is widespread into the regions of Asia Pacific, Europe, Latin America, the Middle East and Africa, and North America. Each of these regions is further classified on the basis of nations. Among these, the market is dominated by North America which is likely to remain the same during the forecast period as well. This is accountable to the presence of notable players, and the presence of advanced medical as well as research facilities in the developed nations. However, Asia Pacific will witness rapid growth in the coming years on account of the increasing investments on improving healthcare infrastructure and facilities in the developing nations, coupled with the rising demand for antibody therapy.